Trending Topic

22 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained less certain. By synthesizing data from nine individual studies, this meta-analysis aimed to quantify the […]

A Selection of Significant Papers from the Past Year as Recommended by the European Endocrine Disease 2006 Advisory Panel

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Mar 28th 2012 European Endocrinology, 2006(1):14; DOI: http://doi.org/10.17925/EE.2006.00.01.14
Select a Section…
1

Article

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy J A, et al.; PROactive investigators.
Lancet (2005);366(9493): pp. 1,279–1,289

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy J A, et al.; PROactive investigators.
Lancet (2005);366(9493): pp. 1,279–1,289

The aim of this study was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. A prospective, randomised controlled trial was performed involving 5,238 patients with type 2 diabetes who had evidence of macrovascular disease. The interpretation made is that pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events.

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Holman R R
Metabolism (2006);55(5 Suppl 1): pp. S2–5.

The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus.

Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis
Meier J J, Kjems L L, Veldhuis J D, Lefebvre P, Butler PC
Diabetes (2006);55(4): pp. 1,051–1,056.

This study concluded that postprandial hyperglucagonemia in type 2 diabetes is likely due to loss of intraislet postprandial suppression of glucagon secretion by insulin.

An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea
Barnett A H, Dreyer M, Lange P, Serdarevic-Pehar M
Diabetes Care (2006);29(6): pp. 1,282–1,287.

An open-label, parallel, 24-week, multicentre trial was performed to compare the efficacy and safety profile of adding inhaled human insulin (INH; Exubera) or metformin to sulfonylurea monotherapy in patients with poorly controlled type 2 diabetes. In patients with type 2 diabetes poorly controlled on a sulfonylurea (A1C >9.5%), the addition of premeal INH significantly improves glycemic control compared with adjunctive metformin and is well tolerated.

Risk factors for renal dysfunction in type 2 diabetes: UK Prospective diabetes study 74
Retnakaran R, Cull C A, Thorne K I, et al.
Diabetes (2006);55(6): pp. 1,832–1,839.

This study sought to identify clinical risk factors at diagnosis of type 2 diabetes associated with later development of renal dysfunction. Over a median of 15 years from diagnosis of type 2 diabetes, nearly 40% of UKPDS patients developed albuminuria and nearly 30% developed renal impairment. Distinct sets of risk factors are associated with the development of these two outcomes, consistent with the concept that they are not linked inexorably in type 2 diabetes.

The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes
Davies M, Brophy S, Williams R, Taylor A
Diabetes Care (2006);29(7): pp. 1,518–1,522.

This study aimed to determine the prevalence of painful diabetic peripheral neuropathy (PDPN) in a population-based sample and to estimate its severity and impact. This study showed a prevalence of PDPN of 26.4%. Having PDPN has a significant negative effect on quality of life, and increasing neuropathy is associated with an increasing risk of developing PDPN.

Ghrelin: from somatotrope secretion to new perspectives in the regulation of peripheral metabolic functions
Broglio F, Prodam F, Riganti F, et al.
Frontiers of Hormone Research (2006);35: pp. 102–114.

Ghrelin, a peptide predominantly produced by the stomach, has been discovered as natural ligand of the GH secretagogue (GHS) receptor type 1a (GHS-R1a), suggesting the existence a new endogenous modulator of somatotrope secretion.

Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysis
Abs R, Feldt-Rasmussen U, Mattsson AF, et al.
European Journal of Endocrinology (2006);155(1): pp. 79–90.

Data for analysis were retrieved from KIMS (Pfizer International Metabolic Database). This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.

Treatment-seeking behavior of erectile dysfunction patients in europe: Results of the Erectile Dysfunction Observational Study
Haro J M, Beardsworth A, Casariego J, Gavart S, Hatzichristou D, et al.
Journal of Sexual Medicine (2006);3(3): pp. 530–540.

This study aimed to present baseline characteristics and treatment-seeking behavior of a large sample of erectile dysfunction (ED) patients recruited in real-life clinical settings. It concluded that unmet need of treatment in ED is high; 66% of patients had experienced ED symptoms for one year or longer when they were looking for treatment. Severity seems to be related to treatment seeking.

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup